A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Hansoh Pharma

Status and phase: Enrolling; Phase 1

Conditions: Advanced Solid Tumor

Treatments: Drug: HS-10386

Study type: Interventional

Funder types: Industry

Identifiers

NCT05911464

HS-10386-101

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.

Full description

This is a phase I open label, multicenter clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of HS-10386 in subjects with advanced solid tumors.

Enrollment: 248 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female, 18-75 years old.
2. Histologically or cytologically documented, incurable or metastatic solid tumors for which standard treatment either does not exist or has proven ineffective or unavailable or intolerable.
3. At least one measurable lesion per RECIST v1.1.
4. Willingness to provide fresh or archival tumor biopsy sample.
5. An Eastern Cooperative Oncology Group (ECOG) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
6. Willingness to use adequate contraceptive measures throughout the study.
7. Ability to comprehend and willingness to sign a written ICF for the study.

Exclusion criteria

1. Treatment with any of the following:

   1. Previous or current treatment with systemic immunotherapy.
   2. Treatment with anticancer medications or investigational drugs within protocol-defined intervals prior to the first scheduled dose of HS-10386.

2. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 except for alopecia.

3. Known additional malignancy.

4. History or risk of autoimmune disease.

5. Known primary CNS malignancy or symptomatic CNS metastases. Patients with asymptomatic CNS metastases may be enrolled after consultation.

6. Inadequate bone marrow reserve or organ function.

7. Clinically significant cardiac disease.

8. Any evidence of severe or uncontrolled systemic diseases

9. Severe infections within 4 weeks prior to the first scheduled dose or symptoms of infection within 2 weeks prior to prior to the first scheduled dose.

10. History of organ transplantation or any medical condition requiring the use of systemic immunosuppressive medications.

11. Active HBV or HCV infection that requires treatment.

12. Known history of HIV.

13. Women who are breastfeeding or have a positive urine or serum pregnancy test at the Screening Visit.

14. Administration of a live, attenuated vaccine within 4 weeks prior to the first scheduled dose or anticipation that such a live attenuated vaccine will be required during the study.

15. History of severe anaphylaxis or allergic to any of the components of HS-10386.

16. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

248 participants in 1 patient group

HS-10386

Experimental group

Description:

Participants will receive HS-10386 once daily. The duration of each treatment cycle is 21 days.

Treatment:

Drug: HS-10386